clinicaltrialsarena4h
BIAL’s first subject completes full dose regimen in Parkinson’s treatment trial
BIAL has completed the full dose regimen for the first subject in the Phase II ACTIVATE trial of BIA 28-6156, for Parkinson's treatment.
clinicaltrialsarena3h
J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial
J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.
clinicaltrialsarena20h
Metsera announces positive results in newest Phase IIa GLP-1RA
The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over competitors’ more frequent regimens.
clinicaltrialsarena23h
Study finds restrictive clinical trial criteria excludes Lyme disease patients
Data from the largest US Lyme disease registry suggests that 90% of PLD patients are excluded from clinical trials.
clinicaltrialsarena23h
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial
Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.